Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.20650 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Dirk Tomsitz und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Immunotherapy, Melanoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adjuvant treatment with anti‐PD1 antibodies has been shown to effectively reduce the risk of recurrence in patients with resected metastatic melanoma. Whether a full 12‐month duration of treatment is needed to achieve full clinical benefit is not known. This study investigated the survival outcome depending on the duration of adjuvant anti‐PD1 therapy.
Methods
From the prospective multicentre real‐world skin cancer registry ADOREG data of 620 patients who finished adjuvant treatment with nivolumab or pembrolizumab for AJCCv8 stage III/IV resected melanoma was analyzed. Recurrence‐free survival (RFS) and overall survival (OS) were compared between patients with regular treatment duration (52 ± 4 weeks; n = 229) and no disease recurrence during therapy (A 1 ) and patients with a premature end of treatment (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
- Department of Dermatology, University Hospital Essen, Essen, Germany.
- German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
- Department of Dermatology, Gesundheit-Nord Hospital, Bremen, Germany.
- Department of Dermatology, DRK Hospital Chemnitz-Rabenstein, Rabenstein, Germany.
- Division of Dermatooncology, Department of Dermatology, University Medical Center, Tuebingen, Germany.
ORCID-Profile: Dirk Tomsitz, Ulrike Leiter, Bastian Schilling, Dirk Schadendorf, Carola Berking
Zitieren
APA
Tomsitz, D., Livingstone, E., Loquai, C., Kaatz, M., Leiter, U., Schilling, B., Terheyden, P., Hassel, J., Sachse, M., Ulrich, J., Dippel, E., Meiss, F., Pföhler, C., Kreuter, A., Herbst, R., Weichenthal, M., Zimmer, L., Meier, F., Rauschenberg, R., …, & Heinzerling, L. (2025). Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20650
Vancouver
Tomsitz D, Livingstone E, Loquai C, Kaatz M, Leiter U, Schilling B, et al. Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20650
BibTeX
@article{Tomsitz2025,
author = {Tomsitz, Dirk and Livingstone, Elisabeth and Loquai, Carmen and Kaatz, Martin and Leiter, Ulrike and Schilling, Bastian and Terheyden, Patrick and Hassel, Jessica and Sachse, Michael and Ulrich, Jens and Dippel, Edgar and Meiss, Frank and Pföhler, Claudia and Kreuter, Alexander and Herbst, Rudolf and Weichenthal, Michael and Zimmer, Lisa and Meier, Friedegund and Rauschenberg, Ricarda and Mohr, Peter and Brunnert, Fiona and von Wasielewski, Imke and Gutzmer, Ralf and Schadendorf, Dirk and Berking, Carola and Ugurel, Selma and Heinzerling, Lucie},
title = {Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.20650}
}
EUVIMED